Fig. 1.

By visit least-squares mean change from baseline in (A) body mass index,^a (B) systolic blood pressure,^b and (C) diastolic blood pressure^b in ENLIGHTEN-2. ^aBased on an analysis of covariance approach using multiple imputation for missing post-baseline assessments. The model included treatment, race, and age group as factors and the baseline value as a covariate. LSM difference (95% CI) of OLZ/SAM versus olanzapine in BMI: −0.65 kg/m² (−1.01, −0.28). ^bBased on an analysis of covariance or logistic regression approach using multiple imputation for missing post-baseline assessments. The model included treatment group as a factor and the baseline value as a covariate. LSM difference (95% CI) for OLZ/SAM versus olanzapine in BP: systolic BP: −2.63 mm Hg (−4.78, −0.47); diastolic BP: −0.75 mm Hg (−2.31, 0.80). BMI, body mass index; BP, blood pressure; HbA1c, glycosylated hemoglobin; LDL, low-density lipoprotein; LSM, least-squares mean; MetS, metabolic syndrome; OLZ/SAM, combination of olanzapine and samidorphan